SavedAdd your journal

Journals / Sağlık Bilimlerinde İleri Araştırmalar Dergisi / 2020 / Cilt: 3 - Sayı: 2

Dental Management in Medication-Related Osteonecrosis of the Jaws and Current Treatment Approachs: Review

İlaca Bağlı Olarak Çene Kemiklerinde Görülen Osteonekrozda Dental Yönetim ve Güncel Tedavi Yaklaşımları: Derleme

Ayşem YURTSEVEN GÜNAY
Gülsüm AK
Pages
81–92
Publication Date
2020-07-10
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In this review, we aimed to provide information about the etiology, risk factors, clinical course, radiological features, current treatment protocols and dental approach of the osteonecrosis that develops due to drug use in the jaws

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Today, antiresorptive and antiangiogenic drugs are used in the treatment of breast, prostate or lung cancer, hypercalcemia, multiple myeloma or osteolytic metastatic lesions.
📊
Key Findings & Data:In addition to these diseases, they can also be used in the treatment of osteoporosis.
💡
Conclusion & Impact:In this review, we aimed to provide information about the etiology, risk factors, clinical course, radiological features, current treatment protocols and dental approach of the osteonecrosis that develops due to drug use in the jaws
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:İlaca bağlı gelişen çene kemiği osteonekrozu · antirezorptif ve antianjiyojenik ilaçlar · dental tedavi yaklaşımları

Abstract

Today, antiresorptive and antiangiogenic drugs are used in the treatment of breast, prostate or lung cancer, hypercalcemia, multiple myeloma or osteolytic metastatic lesions. In addition to these diseases, they can also be used in the treatment of osteoporosis. Depending on the use of these drugs, osteonecrosis may occur in the maxilla and mandible. In this review, we aimed to provide information about the etiology, risk factors, clinical course, radiological features, current treatment protocols and dental approach of the osteonecrosis that develops due to drug use in the jaws

Özet

Günümüzde meme, prostat veya akciğer kanseri, hiperkalsemi, multipl myelom veya osteolitik yapıdaki metastatik lezyonların tedavisinde antirezorptif ve antianjiyojenik ilaçlar kullanılmaktadır. Bu hastalıklara ek olarak osteoporoz tedavisinde de kullanılabilmektedirler. Bu ilaçların kullanımına bağlı olarak, maksilla ve mandibulada osteonekroz oluşabilmektedir. Bu derlemede; çenelerde ilaç kullanımına bağlı olarak gelişen osteonekrozların etiyolojisi, risk faktörleri, klinik seyri, radyolojik özellikleri, güncel tedavi protokolleri ve ayrıca diş hekimi yaklaşımı hakkında bilgi vermeyi amaçladık.

🔖

Cite This Article

GÜNAY, A. Y., AK, G. (2020). Dental Management in Medication-Related Osteonecrosis of the Jaws and Current Treatment Approachs: Review. Sağlık Bilimlerinde İleri Araştırmalar Dergisi, Cilt: 3 - Sayı: 2, 81–92. https://ajindex.com/articles/217113

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Valente NA, Chatelain S, Alfonsi F, Mortellaro C, Barone A. Medication-related osteonecrosis of the jaw. J Craniofac Surg 2019
  2. 1095–101. doi:10.1097/SCS.0000000000005475 2. Yazıcı T, Şentürk MF, Koçer G. İlaca bağlı olarak çene kemiklerinde görülen osteonekroz (Mronj):Derleme. SDÜ Sağlık Bil Enst Derg 2017
  3. 8(2):50-7. doi:10.22312/sdusbed.302041 3. Değim T. Bifosfonatlar ve çene kemiğinde kemik erimesi. Ecza Derg 2006
  4. Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, et al. Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate. Eur Urol 2008
  5. 1066–72. doi:10.1016/j.eururo.2008.06.070 5. Walter C, Al-Nawas B, du Bois A, Buch L, Harter P, Grötz KA. Incidence of bisphosphonateassociated osteonecrosis of the jaws in breast cancer patients. Cancer 2009
  6. 1631–37. doi:10.1002/cncr.24119 6. Van Poznak C, Estilo C. Osteonecrosis of the jaw in cancer patients receiving iv bisphosphonates. Oncology 2006
  7. 20(9):1053–62. 7. Delmas PD, Recker RR, Chesnut CH 3rd, Skag A, Stakkestad JA, Emkey R, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: Results from the bone study. Osteoporos Int 2004
  8. 792–8. doi:10.1007/s00198-004-1602-9 8. Pazianas M, Miller P, Blumentals WA, Bernal M, Kothawala P. A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics. Clin Ther 2007
  9. 1548–58. doi:10.1016/j.clinthera.2007.08.008 9. Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget’s disease of bone: Indications for treatment and review of current therapies. J Bone Miner Res 2006
  10. 94–8. doi:10.1359/jbmr.06s218 10. Hosking D, Lyles K, Brown JP, Fraser WD, Miller P, Curiel MD, et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J Bone Miner Res 2007
  11. 142– 8. doi:10.1359/jbmr.061001 11. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004
  12. 1377–85. doi:10.1016/S01406736(04)16051-0 12. Kamoun-Goldrat A, Ginisty D, Merrer ML. Effect of bisphosphonates on tooth eruption in children with osteogenesis imperfecta. Eur J Oral Sci 2008
  13. 195–8. doi: 10.1111/j.16000722.2008.00529.x 13. Duman AE, Güven GS, Gürlek A. Erkek osteoporozu. Hacettepe Tıp Derg 2005
  14. 175–83. 14. Marx RE. Palmi